Polyethylene glycol (PEG) -lipid conjugates are PEG derivatives containing lipid molecules, such as DMG or DSPE, that have been used for bioconjugation and lipid nanoparticle (LNP) drug delivery to improve the cycle time of liposomal encapsulated drugs. Lipid molecules are characterized by low toxicity and ease of preparation. It can be used as a carrier of both water-soluble and lipid-soluble drugs. Therefore, PEG liposomes can be used to improve drug stability, achieve multi-pathway drug delivery, and achieve targeted drug delivery.
CD Bioparticles’ services with customized delivery strategies, precise designs and modifications of drugs or drug-contained cargos, and advanced technical platforms can help you to solve:
Product Name | Catalog | Form | Unit Size | Price |
---|---|---|---|---|
APRPG Mediated Tumor Angiogensis Targeting Lipid Materials | CDMA079 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-A7R(ATWLPPR) | CDMA056 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-anti-CD133 | CDMA008 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-Anti-CD19 mAb | CDMA005 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-Anti-CD20 mAb | CDMA003 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-anti-CD37 mAb | CDMA014 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-Anti-CD44 | CDMA011 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-anti-EGFR scFv C10 | CDMA022 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-Anti-ErbB2 scFv | CDMA012 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-Anti-HER2 Fab’or scFv F5 | CDMA007 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-Anti-HER2 Fab′ | CDMA020 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-Anti-rat CC531mAb | CDMA030 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-Antinucleosome mAb 2C5 | CDMA009 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-ANTPCGPYTHDCPVKR | CDMA037 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-APRPG | CDMA046 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-ATWLPPR | CDMA055 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-c-dGHCitGPQ-c | CDMA016 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-CD19 mAb HD37 | CDMA001 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-CREKA | CDMA054 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |
DSPE-PEG-cRGD | CDMA077 | Powder | 20 mg, 50 mg, 100 mg | INQUIRY |